Kovack Advisors Inc. Grows Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Kovack Advisors Inc. boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,651 shares of the company’s stock after buying an additional 26 shares during the period. Kovack Advisors Inc.’s holdings in IDEXX Laboratories were worth $1,431,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of IDXX. Norges Bank acquired a new position in IDEXX Laboratories during the fourth quarter worth $512,190,000. International Assets Investment Management LLC raised its holdings in shares of IDEXX Laboratories by 51,631.3% in the 4th quarter. International Assets Investment Management LLC now owns 547,834 shares of the company’s stock valued at $304,075,000 after buying an additional 546,775 shares during the period. Capital Research Global Investors acquired a new position in IDEXX Laboratories during the 4th quarter worth about $135,910,000. TD Asset Management Inc boosted its holdings in IDEXX Laboratories by 178.8% during the 4th quarter. TD Asset Management Inc now owns 260,008 shares of the company’s stock valued at $144,317,000 after acquiring an additional 166,751 shares during the period. Finally, Point72 Asset Management L.P. acquired a new position in IDEXX Laboratories in the 4th quarter valued at about $78,001,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

IDXX opened at $477.49 on Friday. IDEXX Laboratories, Inc. has a 1-year low of $372.50 and a 1-year high of $583.39. The stock has a market cap of $39.44 billion, a P/E ratio of 46.22, a P/E/G ratio of 3.90 and a beta of 1.32. The stock’s 50 day simple moving average is $500.85 and its 200 day simple moving average is $525.26. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.13. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The company had revenue of $964.10 million for the quarter, compared to analyst estimates of $965.43 million. As a group, equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.03 EPS for the current fiscal year.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director Bruce L. Claflin sold 200 shares of IDEXX Laboratories stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $540.80, for a total transaction of $108,160.00. Following the completion of the transaction, the director now owns 161 shares in the company, valued at $87,068.80. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.18% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several research reports. Morgan Stanley reduced their price target on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 14th. Barclays reduced their target price on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, May 2nd. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Stifel Nicolaus cut their price objective on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a research report on Monday, June 24th. Finally, StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Friday, June 14th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $586.63.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.